Anadin Maximum Strength Capsules

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 21/08/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 11/8/2014
print

Print ViewKeyword Search SmPC

Pfizer Consumer Healthcare

Pfizer Consumer Healthcare

Company Products

Medicine NameActive Ingredients
Medicine Name Advil Cold and Flu Coated Tablet Active Ingredients Ibuprofen, Pseudoephedrine Hydrochloride
Medicine Name Anadin Analgesic Tablets Active Ingredients Acetylsalicylic Acid, Caffeine
Medicine Name Anadin Maximum Strength Capsules Active Ingredients Acetylsalicylic acid (Aspirin), Caffeine
Medicine Name Caltrate 500 mg / 1000 IU, chewable tablets Active Ingredients Calcium Carbonate, Colecalciferol (Vitamin D3)
Medicine Name Caltrate 600mg/400IU Film-coated Tablets Active Ingredients Calcium Carbonate, Vitamin D3
Medicine Name Ibuprofen 200mg Soft Capsules Active Ingredients Ibuprofen
Medicine Name Nexium Control 20 mg gastro-resistant tablets Active Ingredients Esomeprazole magnesium trihydrate
Medicine Name Nexium Control Capsules 20mg Esomeprazole Active Ingredients Esomeprazole magnesium trihydrate
Medicine Name Paracetamol 500 mg Film Coated Tablets Active Ingredients Paracetamol
Medicine Name PARAEXTRA Hard Capsules Active Ingredients Caffeine, Paracetamol
Medicine Name Paraeze Hard Capsules Active Ingredients Caffeine, Paracetamol
Medicine Name Robitussin Chesty Cough Active Ingredients Guaifenesin
Medicine Name Robitussin Dry Cough Active Ingredients Dextromethorphan Hydrobromide
Medicine Name Robitussin Plus Active Ingredients Guaifenesin, Pseudoephedrine Hydrochloride
1 - 0 of 14 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 21 August 2020 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Change to packaging

Updated on 20 May 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 20 May 2015 PIL

Reasons for updating

  • Change of manufacturer
  • Change to drug interactions

Updated on 4 March 2015 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 11 August 2014 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through general sale

Updated on 11 August 2014 SmPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

In section 4.2, the following text has been added:
    Method of Administration: Oral

The title of section 4.6 has changed to 'Fertility, Pregnancy and Lactation' and includes the subheadings 'Pregnancy' and 'Lactation'

Section 4.8 has the following text added, as well as the full reporting of side effects to HPRA wording:
    Very rarely Anaemia, Aplastic Anaemia, Pancytopenia

Section 6.6 has changed title to: Special Precautions for disposal

Date of revision of the text has changed from Sep 2013 to May 2014

In section 4.4, the following text has been added:

·     In patients suffering from severe glucose-6-phosphate dehydrogenase (G6PD) deficiency, aspirin is known to rarely cause haemolytic anaemia.

Updated on 24 October 2013 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

In section 10, the date of revision has been changed from June to September 2013

In section 4.8, the following text has been added:

Healthcare professionals are asked to report any suspected adverse reactions preferably through the online reporting option accessible from the IMB homepage. A downloadable report form is also accessible from the IMB website, which may be completed manually and submitted to the IMB via

‘freepost’, in addition to the traditional post-paid ‘yellow card’ option.

 

 

FREEPOST

Pharmacovigilance Section

Irish Medicines Board

Kevin O’Malley House

Earlsfort Centre

Earlsfort Terrace

Dublin 2

Tel: +353 1 6764971

Fax: +353 1 6762517

Website: www.imb.ie

e-mail: imbpharmacovigilance@imb.ie


 

Updated on 23 October 2013 PIL

Reasons for updating

  • Change to storage instructions
  • Change to further information section
  • Change to date of revision
  • Change due to user-testing of patient information
  • Addition of information on reporting a side effect.

Updated on 26 June 2013 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

4.3 Contraindications

• Use in patients hypersensitive (e.g. bronchospasm, rhinitis, urticaria) to the active ingredients or any other constituents.
• History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy. Active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
• Use in patients with bleeding disorders.
• Use in patients with severe heart failure.
• Use in patients who are breast feeding or in the last 3 months of pregnancy.
• Use in children under 16 years.

4.4 Special Warnings and Special Precautions for Use

• The use of Anadin Maximum Strength capsules with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided.
• Undesirable effects may be minimized by using the minimum effective dose for the
shortest duration necessary to control symptoms.
• Elderly: The elderly have an increased frequency of adverse reactions to NSAIDs
especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2)
• Gastrointestinal bleeding, ulceration and perforation: GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events.
• The risk if GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients and also for patients requiring concomitant low dose aspirin or other drugs likely to increase gastrointestinal risk (see below and 4.5)
• Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.
• Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as aspirin (see section 4.5).
• When GI bleeding or ulceration occurs in patients receiving Anadin Maximum Strength capsules, the treatment should be withdrawn.
• NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn’s disease) as their condition may be exacerbated (see sections 4.8 – undesirable effects).
• Patients with a history of, inflammatory bowel disease, coagulation disorders, or asthma should consult a doctor before using this product.
• Aspirin may induce asthmatic attacks in hypersensitive patients.
• There is a possible association between aspirin and Reye’s syndrome when given to children. Reye’s syndrome is a very rare disease, which affects the brain and liver and can be fatal. For this reason, aspirin should not be given to children and adolescents aged under 16 years unless specifically indicated (e.g. Kawasaki’s disease).
• Prolonged use, except under medical supervision, can be harmful. If symptoms persist, the physician should be consulted.
• If you are taking any other medication or are under the care of a doctor you should consult the physician before using.
• In patients with renal, cardiac or hepatic impairment, caution is required since the use of NSAIDs may result in deterioration of renal function. Assessment of renal function should occur prior to the initiation of therapy and regularly thereafter.
• As NSAIDs can interfere with platelet function, they should be used with caution in patients with intracranial haemorrhage and bleeding diathesis.
• There is some evidence that drugs which inhibit cyclo-oxygenase / prostaglandin synthesis may cause impairment of female fertility by an effect on ovulation. This is reversible on withdrawal of treatment.
• Caution is required in patients with a history of hypertension and/or heart failure as fluid retention and oedema have been reported in association with NSAID therapy.
• Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see 4.8). Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Anadin Maximum Strength capsules should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
• Caution should be exercised in patients with dehydration.
• If symptoms persist for more than 3 days, review patients treatment and discontinue treatment if no benefit is seen.

Cardiovascular and cerebrovascular effects:
Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for aspirin.

4.5 Interaction with other medicinal products and other forms of interactions

Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly. However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 5.1).

Care should be taken in patients treated with any of the following drugs as interactions have been reported.

Anti-coagulants: It is considered unsafe to take NSAIDs in combination with warfarin or heparin unless under direct medical supervision as NSAIDs may enhance the effects of anti-coagulants.
Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4).

Anti-hypertensives: reduced anti-hypertensive effect.

Diuretics: reduced diuretic effect. Diuretics can increase the risk of nephrotoxicity of NSAIDs.

Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma cardiac glycoside levels.

Lithium: decreased elimination of lithium.
Methotrexate: decreased elimination of methotrexate.

Cyclosporin: increased risk of nephrotoxicity with NSAIDs

Other NSAIDs: avoid concomitant use of two or more NSAIDs, as this may increase the likelihood of GI side effects

Corticosteroids: increased risk of gastrointestinal bleeding and ulceration.

Aminoglycosides: reduction in renal function in susceptible individuals decreased elimination of aminoglycoside and increased plasma concentrations.

Probenecid: reduction in metabolism and elimination of NSAID and metabolites.

Metoclopramide: increased rate of absorption of aspirin.

Phenytoin: the effect of phenytoin may be enhanced by aspirin. However, no special precautions are needed.

Valproate: the effect of valproate may be enhanced by aspirin.

Oral hypoglycaemic agents: inhibition of metabolism of sulfonylurea drugs, prolonged
half-life and increased risk of hypoglycaemia.

4.6 Pregnancy and Lactation

There is clinical and epidemiological evidence of safety of aspirin in pregnancy, but it may prolong labour and contribute to maternal and neonatal bleeding, and so should not be used in late pregnancy.

During the first and second trimester of pregnancy, aspirin should not be given unless clearly necessary.

Aspirin appears in breast milk and regular high doses may affect neonatal clotting. Not recommended while breast feeding due to possible risk of Reye's Syndrome as well as neonatal bleeding due to hypoprothrombinaemia.

Caffeine appears in breast milk. Irritability and poor sleeping pattern in the infant have been reported.

4.8 Undesirable Effects

Reduced ability of the blood to clot, which may result in easy bruising or bleeding.

Aspirin may precipitate bronchospasm and induce asthma attacks or other hypersensitivity reactions in susceptible individuals.

The most common observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal in the elderly, may occur (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn’s disease (see section 4.4 – Special warnings and precautions for use) have been reported following administration. Less frequently, gastritis has been observed.

Other side effects include asthma, renal urate calculi formation, bleeding and tinnitus. Aspirin may precipitate gout in susceptible individuals.

Bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rare).

Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment.

Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).


Possible risk of Reye’s Syndrome in children under 16 years.

High doses of caffeine can cause tremor and palpitations.


4.9 Overdose

Salicylate poisoning is usually associated with plasma concentrations > 350 mg/l
(2.5 mmol/l). Most adult deaths occur in patients whose concentrations exceed 700 mg/l
(5.1 mmol/L). Single dose less than 100mg/kg are unlikely to cause serious poisoning.

Aspirin
Common features include vomiting, dehydration, tinnitus, vertigo, deafness, sweating, warm extremities with bounding pulses, increased respiratory rate and hyperventilation. Some degree of acid-base disturbance is present in most cases.

A mixed respiratory alkalosis and metabolic acidosis with normal or high arterial pH (normal or reduced hydrogen ion concentration) is usual in adults and children over the age of four years old. In children aged four years or less, a dominant metabolic acidosis with low arterial pH (raised hydrogen ion concentration) is common. Acidosis may increase salicylate transfer across the blood brain barrier.

Uncommon features include haematemesis, hyperpyrexia, hypoglycaemia, hypokalaemia, thrombocytopaenia, increased INR/PTR, intravascular coagulation, renal failure and non-cardiac pulmonary oedema.

Central nervous system features including confusion, disorientation, coma and convulsions are more common in children than adults.

Caffeine
Common features include CNS stimulation; anxiety, nervousness, restlessness, insomnia, excitement, muscle twitching, confusion, convulsions.
Cardiac Symptoms include tachycardia, cardiac arrhythmia. Gastric symptoms include abdominal or stomach pains.
Other symptoms of overdosage, associated with the caffeine component, include diuresis and facial flushing.

Management

Aspirin
Give activated charcoal if an adult presents within one hour of ingestion of more than 250 mg/kg. The plasma salicylate concentration should be measured, although the severity of poisoning cannot be determined from this alone and the clinical and biochemical features must be taken into account. Elimination is increased by urinary alkalinisation, which is achieved by the administration of 1.26% sodium bicarbonate. The urine pH should be monitored. Correct metabolic acidosis with intraveneous 8.4 % sodium bicarbonate (first check serum potassium). Forced diuresis should not be used since it does not enhance salicylate excretion and may cause pulmonary oedema.

Haemodialysis is the treatment of choice for severe poisoning and should be considered in patients with plasma salicylate concentrations > 700 mg/l (5.1 mmol/l), or lower concentrations associated with severe clinical or metabolic features. Patients under 10 years or over 70 years have increased risk of salicylate toxicity and may require dialysis at an earlier stage.

Caffeine
Treatment of caffeine overdose is primarily symptomatic and supportive. Diuresis should be treated by maintaining fluid and electrolyte balance and CNS symptoms can be controlled by intravenous administration of diazepam.

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic Properties

ATC code: N02BE51
Pharmacotherapeutic group: Other analgesics and antipyretics

Aspirin is a non-steroidal anti-inflammatory agent. It has analgesic antipyretic and anti-inflammatory properties.

Caffeine increases the pain relieving effect of the product

Aspirin

Mechanisms of action/effect

Salicylates inhibit the activity of the enzyme cyclo-oxygenase to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Although many of the therapeutic effects may result from inhibition of prostaglandin synthesis (and consequent reduction of prostaglandin activity) in various tissues, other actions may also contribute significantly to the therapeutic effects.

Analgesic
Produces analgesia through a peripheral action by blocking pain impulse generation and via a central action, possibly in the hypothalamus.

Anti-inflammatory (Nonsteriodal)

Exact mechanisms have not been determined. Salicylates may act peripherally in inflamed tissue probably by inhibiting the synthesis of prostaglandins and possibly by inhibiting the synthesis and/or actions of other mediators of the inflammatory response.

Antipyretic
May produce antipyresis by acting centrally on the hypothalamic heat-regulating centre to produce peripheral vasodilation resulting in increased cutaneous blood flow, sweating and heat loss.
Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly. In one study, when a single dose of ibuprofen 400mg was taken within 8 h before or within 30 min after immediate release aspirin dosing (81mg), a decreased effect of ASA on the formation of thromboxane or platelet aggregation occurred. However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use.

Caffeine

Mechanisms of action/effect

Central nervous system stimulant - caffeine stimulates all levels of the CNS, although its cortical effects are milder and of shorter duration than those of amphetamines.

Analgesia adjunct
Caffeine constricts cerebral vasculature with an accompanying decrease in the cerebral blood flow and in the oxygen tension of the brain. It is believed that caffeine helps to relieve headache by providing more rapid onset of action and/or enhancing pain relief with lower doses of analgesic. Recent studies with ergotamine indicate that the enhancement of effect by the addition of caffeine may also be due to improved gastrointestinal absorption of ergotamine when administered with caffeine.

10. DATE OF REVISION OF THE TEXT

June 2013

Updated on 25 June 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to date of revision

Updated on 25 February 2013 SmPC

Reasons for updating

  • Change to section 8 - MA number
  • Change to marketing authorisation holder

Legal category: Supply through general sale

Updated on 18 February 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change to marketing authorisation holder

Updated on 10 May 2012 SmPC

Reasons for updating

  • Change to section 6.1 - List of excipients

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Added excipient; Titanium dioxide.  

Updated on 9 May 2012 PIL

Reasons for updating

  • Change to further information section

Updated on 25 October 2011 SmPC

Reasons for updating

  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

6.1 List of Excipients

Maize starch
Dimethicone
Quinoline yellow (E104)
Titanium Dioxide (E171)
Gelatin
Red iron oxide (E172)
Yellow iron oxide (E172)
Patent blue V (E131)

Printing Ink
Shellac
Iron oxide, black (E172)
Propylene glycol

Updated on 20 October 2011 PIL

Reasons for updating

  • Change to further information section

Updated on 10 August 2010 SmPC

Reasons for updating

  • Change to marketing authorisation holder

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

7.         MARKETING AUTHORISATION HOLDER

 

                        Pfizer Consumer Healthcare Ltd,

                        Ramsgate Road,

                        Sandwich,

                        Kent,

                        CT13 9NJ,

                        UK.

(formally Wyeth Consumer Healthcare)

Updated on 9 August 2010 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 2 December 2009 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5 - Pharmacological properties
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

1. The product name has been changed  as per EU guidance; Anadin Maximum Strength Capsules,
Aspirin 500mg and Caffeine 32mg.
2. Section 4.5 Interactions added ( anticonvulsants and chloramphenicol).
3. Section 4.8, Undesirable effects a reduction in the number of white blood cells, has been added. 
4. Section 5.0, the ATC code has been added.
5. Section 9, the revision of the SPC has been changed to Oct 2009.
6. Section 10, the date of last renewal has been changed to 27 Jan 2009.       

Updated on 30 November 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to date of revision
  • Change to product name

Updated on 20 May 2009 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 4.5 Interactions with other medicinal products
Experimental data suggests that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly. No firm conclusion can be made from this data in relation to regular us of ibuprofen and no clinically relevant effect is considered to be likely for occasional ibuprofen use.

Section 5.1 Pharmacological Properties
Experimental data suggests that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly. In one study, when a single dose of ibuprofen 400mg was taken within 8h before or within 30 min after immediate release aspirin dosing (81mg), a decreased effect of ASA on the formation of thromboxane or platelet aggregation occurred. No firm conclusion can be made from this data in relation to regular us of ibuprofen and no clinically relevant effect is considered to be likely for occasional ibuprofen use.


         

Updated on 13 May 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 15 October 2008 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Variation to update section 4.3, 4.4, 4.5, & 4.8 of the SPC as regards cardiovascular, dermatological, gastrointestinal  & reproductive toxicity

Updated on 15 October 2008 PIL

Reasons for updating

  • Change of contraindications
  • Change to drug interactions
  • Change to side-effects

Updated on 15 December 2006 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Supply through general sale

Updated on 12 December 2006 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Amend section 6.3
Shelf -life increased to 36 months

Updated on 15 July 2005 PIL

Reasons for updating

  • Change to side-effects

Updated on 15 July 2005 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects

Legal category: Supply through general sale

Updated on 19 May 2005 PIL

Reasons for updating

  • Change to storage instructions

Updated on 17 December 2004 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Supply through general sale

Updated on 23 September 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 12 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Supply through general sale